证券代码：603259 证券简称：药明康德 公告编号：临 2024-061 无锡药明康德新药开发股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司董事会披露回购股份决议前一个交易 日（即 2024 年 9 月 10 日）登记在册的前十大股东和前十大无限售条件股东的名 称、持股数量及持股比例公告如下： | 序号 | 前十大股东和前十大无限售条件股东 | 持股数量 | 持股比例 | 股份 | | --- | --- | --- | --- | --- | | | 名称 | （股） | （%） | 种类 | | 1 | HKSCC NOMINEES LIMITED | 387,025,502 | 13.29 | H 股 | | 2 | G&C VI Limited | 143,015,795 | 4.91 | 股 A | | 3 | 香港中央结算有限公司 | 125,866,753 | 4.32 | A 股 | | 4 | G&C IV Hong Kong Limited | 104,626,051 | 3.59 | 股 A | | 5 | 北 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-062 无锡药明康德新药开发股份有限公司 关于 2024 年第三次以集中竞价交易方式首次回购公司股份 暨股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）继前两次分别于 2024 年 2 月 5 日及 2024 年 5 月 22 日累计完成人民币 20 亿元 A 股股份回购后， 公司于 2024 年 9 月 10 日召开第三届董事会第十三次会议，审议并通过了《关于 2024 年第三次以集中竞价交易方式回购公司 A 股股份的议案》，同意公司继续利 用自有资金以集中竞价交易方式回购公司 A 股股份（以下简称"本次回购股份"） 的方案，回购资金总额为人民币 10 亿元，回购价格不超过人民币 61.02 元/股（含）， 回购期限自董事会批准方案之日起不超过 3 个月，回购的股份将全部予以注销并 减少注册资本。具体内容详见公司于 2024 年 9 月 11 日在上海证券交易所网站 （www.sse.co ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-060 无锡药明康德新药开发股份有限公司 关于回购注销部分股票通知债权人的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 6 月 12 日，无锡药明康德新药开发股份有限公司（以下简称"本公 司"或"公司"）召开 2023 年年度股东大会、2024 年第二次 A 股类别股东会议 和 2024 年第二次 H 股类别股东会议，审议通过了《关于给予董事会回购公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规和/或 规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过该议 案经股东大会、A 股及 H 股类别股东会议分别审议通过之日公司已发行 A 股和/ 或 H 股股份数量的 10%。具体内容详见 2024 年 6 月 13 日公司于上海证券交易 所网站及指定媒体披露的《2023 年年度股东大会、2024 年第二次 A 股类别股东 会议及 2024 年第二次 H 股类别股东会议决议公告》（公告编号：20 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-058 公司 2023 年年度股东大会、2024 年第二次 A 股类别股东会议及 2024 年第 二次 H 股类别股东会议审议通过的《关于给予董事会回购公司 A 股和/或 H 股股 份一般性授权的议案》已对董事会办理本次回购股份事宜作出授权，本次回购股 份方案未超出前述授权范围。 1 无锡药明康德新药开发股份有限公司 第三届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2024 年 9 月 10 日向本公司全体董事发出会议通知及会议材料，全体董事一致同意豁免本次 会议的通知期限要求，并以通讯表决方式于 2024 年 9 月 10 日召开第三届董事会 第十三次会议。本次董事会会议应出席董事 12 人，实际出席董事 12 人。会议由 董事长 Ge Li（李革）召集。本次董事会符合《中华人民共和国公司法》和《无 锡药明康德新药开发股份有限公司章程》关于召开董 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-059 无锡药明康德新药开发股份有限公司 关于 2024 年第三次以集中竞价交易方式回购 A 股股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：无锡药明康德新药开发股份有限公司（以下简称"公司"） 继前两次分别于 2024 年 2 月 5 日及 2024 年 5 月 22 日累计完成人民币 20 亿元 A 股股份回购后（具体内容详见公告编号为临 2024-012 及 2024-047 的相关公告）， 公司本次回购资金总额为人民币 10 亿元。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：维护公司价值及股东权益，本次回购的股份将在回购完成之 后全部予以注销并减少注册资本。 ● 回购股份价格：本次回购股份价格不超过人民币 61.02 元/股（含），即不高 于董事会通过本次回购股份决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所系统以集中竞价交易方式回购 A ...

证券代码：603259 证券简称：药明康德 公告编号：临 2024-057 无锡药明康德新药开发股份有限公司 关于澄清事项的进一步公告 有关公司的信息请以公司于上海证券交易所网站（www.sse.com.cn）及指 定信息披露媒体刊登的相关公告为准，请广大投资者理性投资，注意投资风险。 特此公告。 无锡药明康德新药开发股份有限公司董事会 2024 年 9 月 10 日 公司了解到，美国众议院于 2024 年 9 月 9 日（美国时间，下同）就拟议 《生物安全法》通过了一项编号为 H.R.8333 的立法草案。本次通过的立法草案 系基于此前美国众议院监督与问责委员会于 2024年 5月 15日投票所通过的版本 作出（详见编号为临2024-045的相关公告），其中包括将药明康德指定为"予以 关注的生物技术公司"，公司强烈反对这种未经正当程序的预设性且不合理的指 定。该法案拟限制美国政府提供的资金、贷款或补助被用于在履行政府资助的 合同中使用被指定公司提供的某些生物技术设备或服务。尽管有此限制性条款， 该法案也包括了一项不溯及既往条款（"祖父"条款），即允许被指定的公司继 续为其客户履行由美国政府资助的合同直至 2 ...

Financial Performance - The company reported a revenue of RMB 17,240.9 million for the first half of 2024, a decrease of 8.6% compared to RMB 18,871.3 million in the same period of 2023[10]. - Gross profit for the period was RMB 6,700.9 million, down 11.3% from RMB 7,555.7 million year-on-year, resulting in a gross margin of 38.9%[10]. - Net profit attributable to the parent company was RMB 4,239.8 million, reflecting a 20.2% decline from RMB 5,313.1 million in the previous year[10]. - Total revenue for the first half of 2024 was RMB 17,240.9 million, a decrease of 8.6% compared to RMB 18,871.3 million in the same period of 2023[12]. - WuXi Chemistry reported revenue of RMB 12,209.9 million, down 9.3% year-over-year, with a 2.1% increase excluding COVID-19 commercialization projects[13]. - WuXi Testing generated revenue of RMB 3,018.4 million, a decline of 2.4% year-over-year, with laboratory analysis and testing services down 5.4%[15]. - WuXi Biology achieved revenue of RMB 1,168.9 million, a decrease of 5.2% year-over-year, but new molecular-related business grew by 8.1%[16]. - WuXi ATU's revenue was RMB 575 million, down 19.4% year-over-year, primarily due to early-stage commercialization projects and order delays[17]. - Net profit decreased from RMB 5,356.9 million for the six months ended June 30, 2023, to RMB 4,280.8 million for the six months ended June 30, 2024, a year-on-year decrease of 20.1%[22]. - The company reported a total comprehensive income of RMB 4,295,580 thousand, compared to RMB 4,843,228 thousand for the same period last year, indicating a decrease of 11.34%[170]. Customer Base and Market Position - The company maintained a customer base of over 6,000 and added more than 500 new clients during the reporting period[11]. - Revenue from the top 20 global pharmaceutical companies reached RMB 6.59 billion, with an 11.9% increase when excluding COVID-19 projects[11]. - Revenue from U.S. clients was RMB 10.71 billion, a decrease of 1.2% year-on-year when excluding COVID-19 projects[11]. - Revenue from European clients increased by 5.3% to RMB 2.22 billion, while revenue from Chinese clients grew by 2.8% to RMB 3.40 billion[11]. - The company has a global leading "integrated, end-to-end" new drug development service platform, benefiting from the rapid growth of the global drug development outsourcing market[45]. - The company has a large and loyal customer base, covering all of the top 20 global pharmaceutical companies, contributing to a steady increase in both new and existing customers[49]. Financial Position and Assets - Total assets as of June 30, 2024, were RMB 74,397.3 million, a 1.0% increase from RMB 73,669.3 million at the end of 2023[10]. - The company's debt-to-asset ratio increased to 25.9% from 24.6% in the previous period[10]. - Total liabilities as of June 30, 2024, were RMB 19,302.6 million, up from RMB 18,151.9 million as of December 31, 2023, with a debt-to-asset ratio of 25.9%[26]. - The company had total bank borrowings of RMB 5,811.6 million, with RMB 2,919.3 million due within one year[27]. - The company's total assets as of June 30, 2024, included RMB 4,971.0 million in fixed deposits, representing a 32.2% increase from RMB 3,761.4 million at the end of 2023[35]. - The total assets as of June 30, 2024, were RMB 55,094,761 thousand, showing a strong asset base for future growth[176]. Cash Flow and Investments - Net cash generated from operating activities was RMB 4,738.8 million, a decrease of 11.3% compared to the same period in 2023, primarily due to increased payments for production preparations[23]. - Net cash used in investing activities increased by 33.5% to RMB 1,745.9 million, mainly due to increased investments in short-term deposits[24]. - Net cash used in financing activities increased by 32.5% to RMB 3,463.1 million, primarily due to increased payments for A-share repurchases[25]. - The company reported a significant increase in cash received from the sale of financial assets, totaling RMB 2,143,349 thousand, compared to RMB 556,086 thousand in the previous year, representing a growth of 285.5%[177]. - The net cash used in financing activities for the six months ended June 30, 2024, was RMB (2,526,288) thousand, compared to RMB (2,649,084) thousand for the same period in 2023[178]. Research and Development - Research and development expenses for the period were RMB 636,309 thousand, slightly reduced from RMB 667,045 thousand in the previous year[170]. - The company continues to enhance its capabilities in drug formulation, expanding from oral formulations to sterile injectable formulations[46]. - The company is developing multiple new drug candidates and innovative technologies in the fields of peptide drugs, oligonucleotides, and precision medicine[46]. - The company has established a comprehensive high-potency drug research and production capability, providing end-to-end services from active pharmaceutical ingredients to formulations[46]. Shareholder and Incentive Plans - The company approved a cash dividend of RMB 9.8974 per 10 shares for shareholders listed on June 25, 2024[53]. - The company plans to terminate the 2023 H-share incentive trust plan and intends to repurchase and cancel 15,467,500 H-shares[55]. - The company has adopted the 2024 H-share incentive trust plan, approved at the 2023 annual general meeting on June 12, 2024[56]. - The company has implemented various employee incentive plans since 2015 to attract and retain skilled personnel for future development and expansion[110]. - The company’s stock option plans are designed to align employee interests with company performance and shareholder value[109]. Regulatory and Compliance - The company maintained compliance with relevant laws and regulations during the reporting period[164]. - The pharmaceutical R&D services industry is highly regulated, and changes in regulations could adversely affect the company's operations if it fails to adapt its business strategy accordingly[68]. - The company emphasizes compliance and has established internal control systems; however, insufficient oversight of subsidiaries could lead to operational challenges[70]. Market Outlook and Strategy - The company expects 2024 revenue to reach RMB 38.3 billion to RMB 40.5 billion, with a projected growth rate of 2.7% to 8.6% excluding COVID-19 projects[18]. - The global pharmaceutical R&D production service industry is expected to maintain rapid growth, driven by increasing outsourcing by large pharmaceutical companies and rising demand from small and medium-sized pharmaceutical companies[57]. - The company plans to continue expanding its market presence and investing in new product development, focusing on innovative drug research and development[176].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2024年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | 股份類別 A | | ...

Investment Rating - The investment rating for WuXi AppTec (603259.SH) is "Outperform the Market" [5][14]. Core Views - The core business is steadily recovering, with a positive trend in backlog orders. The company reported a total revenue of 17.24 billion yuan in the first half of 2024, a year-on-year decrease of 8.6%, but excluding COVID-19 commercialization projects, the decline is only 0.7%. The net profit attributable to shareholders was 4.24 billion yuan, down 20.2% year-on-year, while the adjusted Non-IFRS net profit was 4.37 billion yuan, down 14.2% year-on-year. The second quarter showed improvement with a revenue of 9.26 billion yuan, a year-on-year decrease of 6.5% but a quarter-on-quarter increase of 16.0% [1][6][8]. Summary by Sections Financial Performance - In the first half of 2024, the chemical business generated revenue of 12.21 billion yuan, a year-on-year decrease of 9.3%, but excluding COVID-19 projects, it increased by 2.1%. Other segments such as testing, biology, and ATU reported revenues of 3.02 billion yuan (down 2.4%), 1.17 billion yuan (down 5.2%), and 570 million yuan (down 19.4%) respectively [9][10]. Business Model and Growth Drivers - The integrated CRDMO model continues to drive development. The small molecule CDMO pipeline expanded with 644 new molecules added in the first half of 2024, including 632 in clinical and preclinical stages, 9 in clinical phase II, 1 in clinical phase III, and 2 commercial projects. The ATU business faced a decline in revenue and gross margin due to proposed legislation in the U.S., but several commercialization projects are actively progressing [10][11]. Order Backlog and TIDES Business - The backlog of orders reached 43.1 billion yuan, showing a year-on-year increase of 33.2% when excluding COVID-19 projects. The TIDES business reported revenue of 2.08 billion yuan in the first half of 2024, a year-on-year increase of 57.2%, with backlog orders growing by 147% [13][14]. Profitability and Financial Metrics - The gross margin for the first half of 2024 was 39.4%, down 1.2 percentage points, while the net margin was 24.8%, down 3.6 percentage points. The company maintained good cost control with a sales expense ratio of 2.1% and a management expense ratio of 10.7% [8][9]. Future Earnings Forecast - The earnings forecast for 2024-2026 remains unchanged, with projected revenues of 39.27 billion yuan, 43.96 billion yuan, and 49.30 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of -2.7%, 11.9%, and 12.1%. The net profit attributable to shareholders is expected to be 9.443 billion yuan, 10.767 billion yuan, and 12.283 billion yuan for the same years, with growth rates of -1.71%, 14.03%, and 14.08% respectively [2][14].

证券代码：603259 证券简称：药明康德 公告编号：临 2024-056 无锡药明康德新药开发股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （三）会议召开方式：上证路演中心视频直播和网络互动 三、参加人员 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2024 年 7 月 30 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药明康 德新药开发股份有限公司 2024 年半年度报告》。为了便于广大投资者更全面深入 地了解本公司 2024 年半年度业绩和经营情况，本公司拟于 2024 年 8 月 30 日（星 期五）上午 10:00-11:00 召开业绩说明会，就投资者普遍关心的问题进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2024 年半年 度业绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普遍 关注的问题进行回答。 二、 业绩说明会召开的时间、地点 ...